Creative Planning acquired a new position in NewLink Genetics Corp (NASDAQ:NLNK) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 18,780 shares of the biotechnology company’s stock, valued at approximately $152,000. Creative Planning owned approximately 0.05% of NewLink Genetics at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its stake in NewLink Genetics by 3.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 556 shares in the last quarter. Advisor Group Inc. lifted its stake in NewLink Genetics by 3.4% in the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 600 shares in the last quarter. Wells Fargo & Company MN lifted its stake in NewLink Genetics by 1.8% in the 2nd quarter. Wells Fargo & Company MN now owns 165,791 shares of the biotechnology company’s stock worth $1,219,000 after acquiring an additional 2,865 shares in the last quarter. State Street Corp lifted its stake in NewLink Genetics by 1.2% in the 2nd quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock worth $2,875,000 after acquiring an additional 4,630 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its stake in NewLink Genetics by 21.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 27,972 shares of the biotechnology company’s stock worth $206,000 after acquiring an additional 4,955 shares in the last quarter. 52.68% of the stock is owned by hedge funds and other institutional investors.

NewLink Genetics Corp (NASDAQ:NLNK) opened at $8.81 on Thursday. NewLink Genetics Corp has a 52-week low of $5.90 and a 52-week high of $25.17. The firm has a market capitalization of $319.12, a PE ratio of -3.61 and a beta of 1.15.

Several research analysts have weighed in on the company. Zacks Investment Research lowered NewLink Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, January 4th. BidaskClub raised NewLink Genetics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. Stifel Nicolaus upped their target price on NewLink Genetics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. Jefferies Group dropped their target price on NewLink Genetics from $26.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. Finally, Cantor Fitzgerald set a $26.00 target price on NewLink Genetics and gave the stock a “buy” rating in a research report on Monday, January 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $23.29.

ILLEGAL ACTIVITY NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/02/08/creative-planning-invests-152000-in-newlink-genetics-corp-nlnk-stock.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Want to see what other hedge funds are holding NLNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewLink Genetics Corp (NASDAQ:NLNK).

Institutional Ownership by Quarter for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.